Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Reasearch ArticleClinical Studies
Open Access

The First Prognostic Tool to Estimate the Risk of Late Grade ≥3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer

DIRK RADES, BRITTA WARWAS, FLORIAN CREMERS, KARSTEN GERULL, RALPH PRIES, ANKE LEICHTLE, KARL L. BRUCHHAGE, SAMER G. HAKIM and STEVEN E. SCHILD
Anticancer Research June 2022, 42 (6) 3035-3039; DOI: https://doi.org/10.21873/anticanres.15789
DIRK RADES
1Departments of Radiation Oncology, and Head and Neck Surgery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dirk.rades@uksh.de
BRITTA WARWAS
1Departments of Radiation Oncology, and Head and Neck Surgery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FLORIAN CREMERS
1Departments of Radiation Oncology, and Head and Neck Surgery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KARSTEN GERULL
1Departments of Radiation Oncology, and Head and Neck Surgery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RALPH PRIES
2Departments of Oto-Rhino-Laryngology and Head and Neck Surgery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANKE LEICHTLE
2Departments of Oto-Rhino-Laryngology and Head and Neck Surgery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KARL L. BRUCHHAGE
2Departments of Oto-Rhino-Laryngology and Head and Neck Surgery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SAMER G. HAKIM
3Oral and Maxillofacial Surgery, University of Lübeck, Lübeck, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEVEN E. SCHILD
4Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Xerostomia is a serious complication following radiotherapy of head-and-neck cancers. A prognostic tool was developed for estimating its risk. Patients and Methods: In our previous study, age, tumor site, bilateral lymph node involvement, definitive radiotherapy, and addition of systemic therapies showed significant associations with grade ≥3 late xerostomia or trends. In additional analyses, mean radiation dose to ipsilateral parotid gland was significant (p=0.011). These six factors were included in the prognostic tool. Scoring points of 0 (lower risk) or 1 (higher risk) were assigned to each factor and added for each patient. Results: Patient scores ranged between 0 and 6; Grade ≥3 xerostomia rates were 0%, 8%, 24%, 26%, 25%, 42%, and 100%, respectively. Three groups were designed (0-1, 2-4, and 5-6 points) with grade ≥3 xerostomia rates of 5%, 25%, and 50%, respectively (p<0.001). Conclusion: This new tool helps estimating the risk of radiation-induced grade ≥3 xerostomia. It can support physicians and other medical staff members during treatment planning.

Key Words:
  • Head-and-neck cancer
  • radiotherapy
  • late xerostomia
  • prognostic tool
  • treatment planning

Xerostomia is considered one of the most dreaded late complications after irradiation of head-and-neck cancers (1). Furthermore, a dry mouth persisting for years can trigger further oral complications such as increased susceptibility to infections, radiation caries, and tooth loss (2-4). Grade ≥2 xerostomia was reported to occur in a considerable proportion of patients irradiated for malignancies in the head-and-neck region, particularly if 3-dimensional conformal radiotherapy (3D-CRT) was used (5-9). For optimization of radiation treatment planning in terms of appropriate coverage of the target volumes and sparing of the organs at risk, comprehensive information regarding the risk of late complications is important. This is particularly true for higher-grade (grade ≥3) toxicities that are serious or potentially life threatening. Grade ≥3 xerostomia is characterized by complete dryness of the mouth, which can be non-debilitating (grade 3) or debilitating (grade 4) for patients (10). Several risk factors have already been identified that can help estimate the risk of radiation-induced xerostomia. The most recognized of these factors is the mean radiation dose to one or both parotid glands (7, 11-14). Moreover, concurrent systemic therapy, and occasionally older age, female sex, tumor sites cranial to the hypopharynx, advanced stage, and bilateral treatment were observed as risk factors for xerostomia (9, 14-16). However, an easy-to-use prognostic tool would be more practical for treating physicians and other medical staff members than separate prognostic factors. Therefore, the present study aimed to create a tool that facilitates estimation of the risk of grade ≥3 late xerostomia after radiotherapy for head-and-neck cancers.

Patients and Methods

In our previous study of 159 patients irradiated for head-and-neck cancers, significant associations with grade ≥3 late xerostomia or trends were found for age ≥61 years (p=0.035), location of the tumor in the nasopharynx, oropharynx and/or oral cavity/floor of mouth (p=0.088), bilateral involvement of lymph nodes (p=0.093), definitive radiotherapy (p=0.082), and the addition of systemic therapies (p=0.055) (5). These five characteristics were used to develop the prognostic tool. Late xerostomia was defined as dryness occurring ≥6 weeks after radiotherapy. It was graded based on the subjective criteria of the Late Effects of Normal Tissues (LENT)/Subjective Objective Management Analytic (SOMA) system with respect to dryness of mouth (as reported by the patients during follow up visits): 0=no dryness; 1=occasional; 2=partial, persistent; 3=complete and not debilitating; 4=complete but debilitating (10). The highest grade of xerostomia observed between 6 weeks and 24 months after radiotherapy was included.

In the present study, which was approved by the ethics committee of the University of Lübeck (AZ 21-108), additional analyses were performed in the initial cohort (n=159) with respect to associations between grade ≥3 xerostomia and the mean radiation doses to the ipsilateral (≤34 vs. >34 Gy, median=34 Gy), the contralateral (≤23 vs. >23 Gy, median=23 Gy) or both (<29 vs. ≥29 Gy, median=28.9 Gy) parotid glands (Table I). A significant association was found for the mean dose to the ipsilateral gland (p=0.011, Chi square test), and trends for associations with the mean dose to the contralateral gland (p=0.078) and both parotid glands (p=0.064). Since these three factors were likely confounding variables, only the significant factor, i.e., the mean dose to the ipsilateral gland, was included in the prognostic tool. Of the patients of the previous study (n=159), complete data regarding the six factors included in the tool were available for 141 patients. Of these patients, 109 received upfront resection of the primary tumor with or without lymph node dissection, and 76 received systemic therapies in addition to radiotherapy. The distributions of these and other patient characteristics are shown in Table II. Details regarding radiotherapy, surgery, and systemic therapies were previously described (5).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Associations between mean radiation doses to ipsilateral, contralateral or both parotid glands and grade ≥3 late xerostomia following radiotherapy.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Distribution of the potential risk factors in the cohort of 141 patients.

For the development of the prognostic tool, the data of these 141 patients were used. For each factor included in the tool, scoring points of 0 (lower risk of xerostomia) or 1 (higher risk) were assigned (Table III) and summed for each patient (patient scores). The creation of prognostic groups was based on the grade ≥3 late xerostomia rates related to the patient scores. The prognostic groups were compared for grade ≥3 late xerostomia rates using the Chisquare test or, in case of <5 patients in one group, the Fisher’s exact test. p-Values <0.05 were considered demonstrating significance and p-values <0.10 showing a trend.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Risk factors for grade ≥3 late xerostomia and related scoring points.

Results

Patient scores ranged between 0 and 6 points. The corresponding grade ≥3 late xerostomia rates were 0% (0/14), 8% (2/26), 24% (7/29), 26% (10/38), 25% (5/20), 42% (5/12), and 100% (2/2), respectively (Figure 1). Based on these rates, three prognostic groups were designed (0-1, 2-4, and 5-6 points) with grade ≥3 late xerostomia rates of 5% (2/40), 25% (22/87), and 50% (7/14), respectively. The overall difference was significant (p=0.001, Chi square test). The differences of 0-1 vs. 2-4 points (p=0.007, Fisher’s exact test) and 0-1 vs. 5-6 points (p<0.001, Fisher’s exact test) were also significant, and the difference of 2-4 vs. 5-6 points showed a strong trend (p=0.057, Chi square test).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The grade ≥3 late xerostomia rates related to the patient scores.

Discussion

Following radiotherapy of head-and-neck cancers, patients may experience late xerostomia, which can result in significant additional complications including oral mucosal discomfort and infections, dysgeusia, weight loss, and carious destruction of teeth (2-4). This is particularly true for grade ≥3 xerostomia, which is defined as complete dryness of mouth (10). Thus, grade ≥3 xerostomia should be avoided, whenever reasonably possible. Since the risk of late xerostomia increases with the mean radiation dose at the parotid glands, it is important to spare these glands when planning the treatment (7, 11-14). In head-and-neck cancer patients with lymph node involvement, particularly in case of N2c or N3 disease, sparing of parotid glands may have a negative impact on the dose coverage of the target volumes resulting in a higher risk of loco-regional recurrences. For optimal results of radiation treatment planning, it would be helpful to be able to estimate a patient’s risk of developing grade ≥3 late xerostomia. A higher risk would mean a greater need of sparing the parotid glands.

In addition to the mean dose to the parotid glands, other risk factors for post-radiotherapy xerostomia have been reported (7, 11-16). However, it may be difficult to estimate the risk with separate prognostic factors for each individual patient. More practical for clinical use would be an easy-to-use scoring system combining prognostic factors. The present study was performed to develop such a tool in a cohort of patients receiving radiotherapy plus/minus chemotherapy for head-and-neck cancers. The prognostic tool was based on six factors that were significantly associated with the occurrence of grade ≥3 xerostomia or showed a corresponding trend. These factors included age, location of the tumor, bilateral lymph node involvement, definitive treatment, addition of systemic therapies, and mean radiation dose to the ipsilateral parotid gland. Considering the rates of grade ≥3 xerostomia related to these factors, three prognostic groups were designed, namely 0-1, 2-4, and 5-6 points. In the 0-1 points group, the risk of grade ≥3 late xerostomia was low. The 5% probability represents the complication rate, which is generally considered tolerable (tolerance dose=TD5/5) (17). Therefore, one may consider to focus more on the coverage of the target volumes during radiation treatment planning in these patients. In the 2-4 points group, the probability of developing grade ≥3 late xerostomia was 25%. This rate is a bit higher than the 20% considered acceptable in the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) (18). Thus, sparing of the parotid glands becomes more important in this group. In the 5-6 points group, every second patient developed grade ≥3 late xerostomia. Therefore, sparing of the parotid glands is of great importance for these patients. However, when one has to weigh between sparing of the parotid glands and coverage of the target volumes, it is very important that the patient participates in the decision process. The patients’ preference regarding better loco-regional control of the disease versus less toxicity including xerostomia must have the highest priority.

When planning to use this prognostic tool, one should be aware of the limitations of the present study. These limitations include the retrospective nature of the data used for the tool (risk of hidden selection biases) and the fact that grading of xerostomia was limited to subjective criteria of the LENT/SOMA system. Moreover, validation of this new tool is warranted.

In summary, a prognostic tool including three groups was developed to estimate the risk of grade ≥3 late xerostomia after radiotherapy of head-and-neck cancers. This new tool can support physicians, dosimetrists, and medical physicists during treatment planning. However, the limitations of this study should be considered when using this new tool that should be validated. It is important that patients participate in the decision process regarding improved loco-regional control versus less xerostomia.

Footnotes

  • Authors’ Contributions

    All Authors participated in the design of the study. The data were provided by B.W. and interpreted by all Authors. D.R. and S.E.S. drafted the article, which was reviewed and approved by all Authors.

  • Conflicts of Interest

    The Authors have no conflicts of interest to declare in relation to this study.

  • Received April 12, 2022.
  • Revision received April 27, 2022.
  • Accepted April 29, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Deboni AL,
    2. Giordani AJ,
    3. Lopes NN,
    4. Dias RS,
    5. Segreto RA,
    6. Jensen SB and
    7. Segreto HR
    : Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer. Support Care Cancer 20(11): 2903-2911, 2012. PMID: 22410861. DOI: 10.1007/s00520-012-1418-7
    OpenUrlCrossRefPubMed
  2. ↵
    1. Mercadante V,
    2. Jensen SB,
    3. Smith DK,
    4. Bohlke K,
    5. Bauman J,
    6. Brennan MT,
    7. Coppes RP,
    8. Jessen N,
    9. Malhotra NK,
    10. Murphy B,
    11. Rosenthal DI,
    12. Vissink A,
    13. Wu J,
    14. Saunders DP and
    15. Peterson DE
    : Salivary gland hypofunction and/or xerostomia induced by nonsurgical cancer therapies: ISOO/MASCC/ASCO guideline. J Clin Oncol 39(25): 2825-2843, 2021. PMID: 34283635. DOI: 10.1200/JCO.21.01208
    OpenUrlCrossRefPubMed
    1. Kovarik JP,
    2. Voborna I,
    3. Barclay S,
    4. Nicol A,
    5. Kelly C,
    6. Kovarik PD,
    7. Iqbal MS and
    8. Kovarik J
    : Dental loss after radiotherapy for head and neck cancer. Br Dent J 231(8): 473-478, 2021. PMID: 34686814. DOI: 10.1038/s41415-021-3536-4
    OpenUrlCrossRefPubMed
  3. ↵
    1. Deng J,
    2. Jackson L,
    3. Epstein JB,
    4. Migliorati CA and
    5. Murphy BA
    : Dental demineralization and caries in patients with head and neck cancer. Oral Oncol 51(9): 824-831, 2015. PMID: 26198979. DOI: 10.1016/j.oraloncology.2015.06.009
    OpenUrlCrossRefPubMed
  4. ↵
    1. Warwas B,
    2. Cremers F,
    3. Gerull K,
    4. Leichtle A,
    5. Bruchhage KL,
    6. Hakim SG,
    7. Schild SE and
    8. Rades D
    : Risk factors for xerostomia following radiotherapy of head-and-neck cancers. Anticancer Res 42(5): 2657-2663, 2022. DOI: 10.21873/anticanres.15743
    OpenUrlAbstract/FREE Full Text
    1. Rades D,
    2. Stoehr M,
    3. Meyners T,
    4. Bohlen G,
    5. Nadrowitz R,
    6. Dunst J,
    7. Schild SE,
    8. Wroblewski J,
    9. Albers D,
    10. Schmidt R,
    11. Alberti W and
    12. Tribius S
    : Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. Strahlenther Onkol 184(4): 198-205, 2008. PMID: 18398584. DOI: 10.1007/s00066-008-1825-3
    OpenUrlCrossRefPubMed
  5. ↵
    1. Rodrigues NA,
    2. Killion L,
    3. Hickey G,
    4. Silver B,
    5. Martin C,
    6. Stevenson MA,
    7. Mauch PM and
    8. Ng AK
    : A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. Int J Radiat Oncol Biol Phys 75(4): 1079-1083, 2009. PMID: 19327910. DOI: 10.1016/j.ijrobp.2008.12.053
    OpenUrlCrossRefPubMed
    1. Rades D,
    2. Fehlauer F,
    3. Wroblesky J,
    4. Albers D,
    5. Schild SE and
    6. Schmidt R
    : Prognostic factors in head-and-neck cancer patients treated with surgery followed by intensity-modulated radiotherapy (IMRT), 3D-conformal radiotherapy, or conventional radiotherapy. Oral Oncol 43(6): 535-543, 2007. PMID: 17005437. DOI: 10.1016/j.oraloncology.2006.05.006
    OpenUrlCrossRefPubMed
  6. ↵
    1. Aggarwal P,
    2. Hutcheson KA,
    3. Garden AS,
    4. Mott FE,
    5. Lu C,
    6. Goepfert RP,
    7. Fuller CD,
    8. Lai SY,
    9. Gunn GB,
    10. Chambers MS,
    11. Sturgis EM,
    12. Hanna EY and
    13. Shete S
    : Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. Cancer 127(23): 4470-4480, 2021. PMID: 34358341. DOI: 10.1002/cncr.33849
    OpenUrlCrossRefPubMed
  7. ↵
    LENT SOMA tables. Radiother Oncol 35(1): 17-60, 1995. PMID: 7569012.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Eisbruch A,
    2. Ten Haken RK,
    3. Kim HM,
    4. Marsh LH and
    5. Ship JA
    : Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 45(3): 577-587, 1999. PMID: 10524409. DOI: 10.1016/s0360-3016(99)00247-3
    OpenUrlCrossRefPubMed
    1. Dijkema T,
    2. Raaijmakers CP,
    3. Ten Haken RK,
    4. Roesink JM,
    5. Braam PM,
    6. Houweling AC,
    7. Moerland MA,
    8. Eisbruch A and
    9. Terhaard CH
    : Parotid gland function after radiotherapy: the combined michigan and utrecht experience. Int J Radiat Oncol Biol Phys 78(2): 449-453, 2010. PMID: 20056347. DOI: 10.1016/j.ijrobp.2009.07.1708
    OpenUrlCrossRefPubMed
    1. Hey J,
    2. Setz J,
    3. Gerlach R,
    4. Janich M,
    5. Hildebrandt G,
    6. Vordermark D,
    7. Gernhardt CR and
    8. Kuhnt T
    : Parotid gland-recovery after radiotherapy in the head and neck region – 36 months followup of a prospective clinical study. Radiat Oncol 6: 125, 2011. PMID: 21951317. DOI: 10.1186/1748-717X-6-125
    OpenUrlCrossRefPubMed
  9. ↵
    1. Beetz I,
    2. Schilstra C,
    3. Burlage FR,
    4. Koken PW,
    5. Doornaert P,
    6. Bijl HP,
    7. Chouvalova O,
    8. Leemans CR,
    9. de Bock GH,
    10. Christianen ME,
    11. van der Laan BF,
    12. Vissink A,
    13. Steenbakkers RJ and
    14. Langendijk JA
    : Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. Radiother Oncol 105(1): 86-93, 2012. PMID: 21632133. DOI: 10.1016/j.radonc.2011.05.010
    OpenUrlCrossRefPubMed
    1. Teguh DN,
    2. Levendag PC,
    3. Ghidey W,
    4. van Montfort K and
    5. Kwa SL
    : Risk model and nomogram for dysphagia and xerostomia prediction in head and neck cancer patients treated by radiotherapy and/or chemotherapy. Dysphagia 28(3): 388-394, 2013. PMID: 23355106. DOI: 10.1007/s00455-012-9445-6
    OpenUrlCrossRefPubMed
  10. ↵
    1. Owosho AA,
    2. Thor M,
    3. Oh JH,
    4. Riaz N,
    5. Tsai CJ,
    6. Rosenberg H,
    7. Varthis S,
    8. Yom SH,
    9. Huryn JM,
    10. Lee NY,
    11. Deasy JO and
    12. Estilo CL
    : The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. J Craniomaxillofac Surg 45(4): 595-600, 2017. PMID: 28256385. DOI: 10.1016/j.jcms.2017.01.020
    OpenUrlCrossRefPubMed
  11. ↵
    1. Emami B,
    2. Lyman J,
    3. Brown A,
    4. Coia L,
    5. Goitein M,
    6. Munzenrider JE,
    7. Shank B,
    8. Solin LJ and
    9. Wesson M
    : Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1): 109-122, 1991. PMID: 2032882. DOI: 10.1016/0360-3016(91)90171-y
    OpenUrlCrossRefPubMed
  12. ↵
    1. Marks LB,
    2. Yorke ED,
    3. Jackson A,
    4. Ten Haken RK,
    5. Constine LS,
    6. Eisbruch A,
    7. Bentzen SM,
    8. Nam J and
    9. Deasy JO
    : Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76(3 Suppl): S10-S19, 2010. PMID: 20171502. DOI: 10.1016/j.ijrobp.2009.07.1754
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (6)
Anticancer Research
Vol. 42, Issue 6
June 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The First Prognostic Tool to Estimate the Risk of Late Grade ≥3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The First Prognostic Tool to Estimate the Risk of Late Grade ≥3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer
DIRK RADES, BRITTA WARWAS, FLORIAN CREMERS, KARSTEN GERULL, RALPH PRIES, ANKE LEICHTLE, KARL L. BRUCHHAGE, SAMER G. HAKIM, STEVEN E. SCHILD
Anticancer Research Jun 2022, 42 (6) 3035-3039; DOI: 10.21873/anticanres.15789

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The First Prognostic Tool to Estimate the Risk of Late Grade ≥3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer
DIRK RADES, BRITTA WARWAS, FLORIAN CREMERS, KARSTEN GERULL, RALPH PRIES, ANKE LEICHTLE, KARL L. BRUCHHAGE, SAMER G. HAKIM, STEVEN E. SCHILD
Anticancer Research Jun 2022, 42 (6) 3035-3039; DOI: 10.21873/anticanres.15789
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Effect of Postoperative Muscle Loss After Resection of Non-small Cell Lung Cancer on Surgical Outcomes
  • The Prognostic Relevance of Preoperative CEA and CA19-9 for Ampulla of Vater Carcinoma
  • Difference in the Overall Survival Between Malignant Central Airway Obstruction Patients Treated by Transbronchial Microwave Ablation and Stent Placement: A Single-institution Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • Head-and-neck cancer
  • radiotherapy
  • late xerostomia
  • prognostic tool
  • treatment planning
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire